Jacqueline Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacqueline Wang has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Michael Wang
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
19 shared publications - Bingliang Fang
Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
18 shared publications Shengjian Huang
18 shared publicationsDavid Santos
17 shared publicationsLaura Lam
17 shared publicationsMaria Badillo
17 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
Survival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis
- 11 August 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
Open AccessSurvival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3. Treatment profiling of PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Freshly isolated lymphoma cells from PT2-BL-G6 and G7 PDXs. Cell viability was tested by CellTiter-Glo luminescent cell viability assay after 48-hour incubation with the indicated drug treatment. The in vitro drug and dose information for IBN and ABT-199 are listed in Supplementary Table S1. IBN, ibrutinib; PT, patient; BL, Burkitt's lymphoma.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3. Treatment profiling of PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Freshly isolated lymphoma cells from PT2-BL-G6 and G7 PDXs. Cell viability was tested by CellTiter-Glo luminescent cell viability assay after 48-hour incubation with the indicated drug treatment. The in vitro drug and dose information for IBN and ABT-199 are listed in Supplementary Table S1. IBN, ibrutinib; PT, patient; BL, Burkitt's lymphoma.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
A, Schematic describing the primary B-cell lymphoma PDX SCID/NSG-hu mouse model. Six-to 8-week-old male NSG or CB-17 SCID mice were implanted with human fetal bone. Approximately 4 to 6 weeks following bone implantation, one injection of 5 Ã- 106 patient tumor cells were administered directly into the human fetal bone chip as the first generation (G1). The levels of circulating human β2M in mouse serum were used to monitor tumor engraftment and growth in G1 mice. Once tumor burden was detected, the pieces of tumor with bone chip were subcutaneously transplanted into NSG mice as the second generation (G2). After G2, the consistent growths of tumor in NSG mice were acquired. Single-agent targeted therapy, drug-resistant treatment, or combination therapy, were administered in the indicated generations. B, Human β2M reflected the tumor burdens of 16 B-cell lymphomas in PDX-G1 mice. After 3-4 weeks of tumor inoculation, mouse sera were collected from the peripheral blood of tail vein, and the level of human β2M was determined by ELISA.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
A, Schematic describing the primary B-cell lymphoma PDX SCID/NSG-hu mouse model. Six-to 8-week-old male NSG or CB-17 SCID mice were implanted with human fetal bone. Approximately 4 to 6 weeks following bone implantation, one injection of 5 Ã- 106 patient tumor cells were administered directly into the human fetal bone chip as the first generation (G1). The levels of circulating human β2M in mouse serum were used to monitor tumor engraftment and growth in G1 mice. Once tumor burden was detected, the pieces of tumor with bone chip were subcutaneously transplanted into NSG mice as the second generation (G2). After G2, the consistent growths of tumor in NSG mice were acquired. Single-agent targeted therapy, drug-resistant treatment, or combination therapy, were administered in the indicated generations. B, Human β2M reflected the tumor burdens of 16 B-cell lymphomas in PDX-G1 mice. After 3-4 weeks of tumor inoculation, mouse sera were collected from the peripheral blood of tail vein, and the level of human β2M was determined by ELISA.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2. Characterization of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Representative tumor mass and histology of tumor series passages of PT1 MCL and PT2 Burkitt's lymphoma (BL). B-C, PDX tumors invaded the mouse spleen and formed splenomegaly. D, Patient abdomen PET/CT images of PT1 and PT5 showed splenomegaly (left panel). Autopsy of PT1 G3 NSG mouse and PT5 G1 SCID-hu mouse also showed splenomegaly (middle panel), and H&E staining of mouse spleens in PDXs indicated extensive lymphoma involvement (right panel).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2. Characterization of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Representative tumor mass and histology of tumor series passages of PT1 MCL and PT2 Burkitt's lymphoma (BL). B-C, PDX tumors invaded the mouse spleen and formed splenomegaly. D, Patient abdomen PET/CT images of PT1 and PT5 showed splenomegaly (left panel). Autopsy of PT1 G3 NSG mouse and PT5 G1 SCID-hu mouse also showed splenomegaly (middle panel), and H&E staining of mouse spleens in PDXs indicated extensive lymphoma involvement (right panel).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4. Carfilzomib overcomes primary ibrutinib resistance in vivo from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
PT8 was clinically primary ibrutinib resistant. PT8-MCL PDX was generated and passaged. G3 mice were treated with vehicle control, IBN, and CFZ (P < 0.01, CFZ versus vehicle control or IBN, n = 5).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4. Carfilzomib overcomes primary ibrutinib resistance in vivo from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
PT8 was clinically primary ibrutinib resistant. PT8-MCL PDX was generated and passaged. G3 mice were treated with vehicle control, IBN, and CFZ (P < 0.01, CFZ versus vehicle control or IBN, n = 5).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3. OncoPlus Gene List and Identified Variants from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Supplementary Table S3. OncoPlus Gene List and Identified Variants
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3. OncoPlus Gene List and Identified Variants from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Supplementary Table S3. OncoPlus Gene List and Identified Variants